LEADER 05223nam 2200625Ia 450 001 9910144091303321 005 20200520144314.0 010 $a1-281-93942-0 010 $a9786611939427 010 $a0-470-69704-0 010 $a0-470-69703-2 035 $a(CKB)1000000000551643 035 $a(EBL)366841 035 $a(OCoLC)476202034 035 $a(SSID)ssj0000104135 035 $a(PQKBManifestationID)11113841 035 $a(PQKBTitleCode)TC0000104135 035 $a(PQKBWorkID)10079551 035 $a(PQKB)11133591 035 $a(MiAaPQ)EBC366841 035 $a(PPN)190253940 035 $a(EXLCZ)991000000000551643 100 $a20080530d2008 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAnticancer therapeutics /$fedited by Sotiris Missailidis 210 $aChichester ;$aHoboken, NJ $cJohn Wiley & Sons$d2008 215 $a1 online resource (426 p.) 300 $aDescription based upon print version of record. 311 $a0-470-72303-3 320 $aIncludes bibliographical references and index. 327 $aAnticancer Therapeutics; Contents; Forward; Acknowledgements; List of contributors; SECTION I: Development of Anticancer Therapeutics; 1 Exploring the Potential of Natural Products in Cancer Treatment; 1.1 Introduction; 1.2 Sources; 1.3 Different Approaches to the Search for Bioactive Natural Products; 1.4 Methodologies of Lead Compound or New Drug Identification; 1.5 Chemoprevention - A New Area for Natural Product Research; 1.6 Concluding Remarks; 2 Combinatorial Approaches to Anticancer Drug Design; 2.1 Introduction; 2.2 Combinatorial Approaches for Small Molecule Drug Design 327 $a2.3 Display Technologies2.4 Aptamer Selection; 2.5 Conclusions; 3 Rational Approaches to Anticancer Drug Design/in silico Drug Development; 3.1 Introduction; 3.2 Approaches to the Drug Discovery Process in Anticancer Research; 3.3 Ligand-based Examples; 3.4 Structure-based Examples; 3.5 Conclusions; SECTION II: Anticancer Therapeutics; 4 Introduction to Anticancer Therapeutics; 4.1 Problems in cancer; 4.2 Cancer treatments; 4.3 Classification of chemotherapy drugs; 5 Platinum Drugs; 5.1 Cisplatin; 5.2 Lipoplatin; 5.3 Carboplatin; 5.4 Oxaliplatin; 5.5 Lipoxal; 5.6 New Platinum Compounds 327 $a5.7 Cisplatin Resistance and Chemotherapy6 Antimicrotubule Agents; 6.1 Taxanes; 6.2 Vinca Alkaloids; 6.3 Mechanisms of Resistance to Antimicrotubule Agents; 7 Antimetabolites in Cancer Therapy; 7.1 Introduction; 7.2 Folate Antagonists; 7.3 Pyrimidine Antagonists; 7.4 Purine Antagonists; 7.5 Summary; 8 Antitumour Antibiotics; 8.1 Introduction; 8.2 Actinomycin; 8.3 Mitomycin C; 8.4 Bleomycin; 8.5 Anthracyclines; 8.6 Trabectedin (Ecteinascidin, ET-743); 8.7 Camptothecins; 8.8 Podophyllotoxins; 9 Alkylating Agents; 9.1 Introduction; 9.2 Nitrogen Mustards; 9.3 Methylmelamines and Ethylenimines 327 $a9.4 Methylhydrazine Derivatives9.5 Alkylsulfonates; 9.6 Nitrosoureas; 9.7 Triazenes; 10 Hormone Therapies; 10.1 Introduction; 10.2 Oestrogen Receptor Targeted Therapeutics; 10.3 Progesterone-Targeted Therapy; 10.4 Neuroendocrine Tumours; 11 Photodynamic Therapy of Cancer; 11.1 Introduction; 11.2 Photosensitizers; 11.3 Outlook; 11.4 Acknowledgement; 12 Target-directed Drug Discovery; 12.1 Introduction; 12.2 Tyrosine Kinases - Role and Significance in Cancer; 12.3 Targeted Therapy for the Treatment of Non-small Cell Lung Cancer (NSCLC) 327 $a12.4 Targeted Therapy for the Treatment of Chronic Myeloid Leukaemia12.5 Targeted Therapy for the Treatment of Breast Cancer; 12.6 Angiogenesis; 12.7 Targeting Cell Cycling; 12.8 Targeting Apoptosis; 12.9 Targeting mTOR; 12.10 The Future of Molecularly Targeted Therapy; 13 Tumour Hypoxia: Malignant Mediator; 13.1 Introduction; 13.2 Hypoxia Inducible Factor-1 and Hypoxia; 13.3 HIF-1? Post-translational Changes; 13.4 How Genetics Can Modify HIF; 13.5 How Tumours Overcome Hypoxia with HIF-1; 13.6 HIF-1 Therapeutics; 13.7 Conclusion; 14 Resistance to Chemotherapy Drugs; 14.1 Introduction 327 $a14.2 What are the Factors Limiting the Efficacy of Cancer Chemotherapy Treatment? 330 $aWritten by the winner of the 2008 Mike Price Fellowship ""This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject."" Anticancer Research, November - December 2008 This book provides a clear introduction to the area, with an overview of the various drug design and development approaches for cancer therapeutics and their progress in today's multidisciplinary approach to cancer treatment. Clearly structured throughout, the book not only provides information on currently used molecular treatment a 606 $aCancer$xChemotherapy 606 $aAntineoplastic agents 615 0$aCancer$xChemotherapy. 615 0$aAntineoplastic agents. 676 $a616.99/4061 676 $a616.994061 701 $aMissailidis$b Sotiris$0885913 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144091303321 996 $aAnticancer therapeutics$91978114 997 $aUNINA